This is a website for healthcare professionals.
The First Personalized Rule-In Drug Response Test For RA Therapies
Rheumatoid arthritis (RA) is an autoimmune disease that mainly attacks the synovial tissues within the joints. There are currently ~2 million1 RA patients in America, with 120,0001 new diagnoses each year.
Exagen Inc. has partnered with Queen Mary University of London to develop novel patented molecular signatures for rheumatoid arthritis biologic therapeutic selection. The result provides rheumatologists the ability to reliably predict positive patient response prior to the selection of commonly prescribed biological therapeutic agents.
RA patients experience a low response rate
to existing therapeutics
Of the $30 Billion2 spent in America each year on RA therapeutics, an estimated $18 Billion is wasted due to low response rates.
Do NOT achieve an
ACR20 response
Do NOT achieve an
ACR50 response
Do NOT achieve an
ACR 70 response
Pitzalis et al. Nature Reviews Rheumatology. 2020
*ACR response rates include all RA therapeutics
Our Unique 'Individual Patient Signature' Helps Guide Treatment
An 'Individual Patient Signature' is based on the following features:
Clinical disease activity indices
Gene expression analysis performed on synovial tissue
Conventional RA lab tests
Source: Ribera et al. Annals of
Rheumatic Diseases. 2019
Existing Patient Journey 3
Once a patient fails to respond, a healthcare provider has 12 drugs to choose from with no current rule-in test to direct their decision.
AVISE RADR Patient Journey
Speed and accuracy in testing has the potential of protecting a patient's joints and is cost effective
AVISE RADR brings personalized precision oncology-style drug response testing to rheumatology
Innovative
First rule-in test for
rheumatoid arthritis therapies
Accelerates Treatment
Shortens time to efficacious treatment
and disease control
Healthcare Benefits
Stops patient cycling
Increases cost savings
Want to learn more about AVISE RADR?
Exagen aids patients and healthcare providers in the diagnosis, prognosis, and management of autoimmune conditions.
To learn more about AVISE® RADR complete this form and an Exagen representative will contact you.
Sources:
- Myasoedova et al. Arthritis & Rheumatology 2010 .
- IQVIA DDD Data; IBM Truven patient claims data; Cowen Therapeutic Categories Outlook Feb 2021
- Lewis et al. Cell Reports. 2019